MediStem Laboratories, Inc. MDSM Archives - Page 4 of 4

MondayJan 29, 2007 5:58 am

The Work of Medistem Laboratories, Inc. (MDSM) has Potential Application in Humans, to Induce the Generation of New Blood Vessels

Based on initial animal studies, cord blood stem cells are potentially capable of generating new blood vessels. Medistem Laboratories, Inc. (MDSM), is currently in discussions with several academic institutions for completion of pre-clinical studies. This has the potential to enable an Investigational New Drug filing with the FDA, anticipated in the second half of 2007. This key research is hoped to benefit the 750,000 people in the U.S. alone that suffer from critical limb ischemia. Let us hear your thoughts below:

SaturdayJan 27, 2007 5:14 pm

Medistem Laboratories, Inc. (MDSM) Boasts Robust Portfolio of Intellectual Property Assets

Medistem Laboratories, Inc. (MDSM) has an rich intellectual property portfolio. From the outset, the Company chose to generate revenues from these assets, by offering licenses of its know-how, trade secrets and intellectual property. Medistem's trade secrets and know-how cover ways of generating and practically using adult stem cells in a variety of clinical settings. This licensing program allows modern day stem cell technology, to be utilized in government approved clinics. Let us hear your thoughts below:

SaturdayJan 27, 2007 1:31 pm

Medistem Laboratories, Inc. (MDSM) Aims For Health Breakthroughs with its Mission

Medistem Laboratories, Inc. (MDSM) is opening the new frontier in medicine, seeking health breakthroughs, with its stated mission. The Medistem Laboratories mission is to commercialize adult stem cell therapeutic platforms in the U.S., through being a provider to the therapeutic pipeline of Big Pharma, while at the same time out-licensing various technologies to entities around the world in the treatment of disease. Let us hear your thoughts below:

FridayJan 26, 2007 8:11 am

New Product Induces Formation of New Blood Vessels and Results in Patent Application Filed by Medistem Laboratories, Inc. (OTCBB: MDSM.OB)

Medistem Laboritories recently announced that it has filed a patent application covering the Angiostem(TM) platform, a technology with potential to benefit cardiac and limb ischemic diseases. Angiostem(TM) is planned to be the company's first pipeline product intended for US Commercialization. If approved for human use, the Angiostem(TM) platform will alllow for the manipulation of cord blood so as to enable it to be used by different individuals without the need for immune suppression. Let us hear your thoughts below:

Site Search

Company Search

Tag: MediStem Laboratories, Inc. MDSM

The Work of Medistem Laboratories, Inc. (MDSM) has Potential Application in Humans, to Induce the Generation of New Blood Vessels

Medistem Laboratories, Inc. (MDSM) Boasts Robust Portfolio of Intellectual Property Assets

Medistem Laboratories, Inc. (MDSM) Aims For Health Breakthroughs with its Mission

New Product Induces Formation of New Blood Vessels and Results in Patent Application Filed by Medistem Laboratories, Inc. (OTCBB: MDSM.OB)

Market Basics

Newsletter Publishers

Public Companies